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There is evidence for an inhibition of interferon- antiviral activity by the hepatitis C viral protein, NS5A. To identify the
mechanisms through which NS5A blocks interferon activity, we compared the gene expression profile of interferon-treated
Huh7 cells, stably expressing NS5A with control, using microarrays. Following interferon treatment, 50 genes were
up-regulated by at least twofold in control clones, whereas induction of 9 of the 50 genes was significantly reduced in
NS5A-expressing clones. The strongest effect of NS5A on interferon response was observed for the OAS-p69 gene.
Remarkably, Huh7 cells expressing NS5A showed an up-regulation of interleukin-8. Up-regulation of interleukin-8 was also
observed upon transient expression of NS5A mutants isolated from patients responsive or resistant to interferon therapy.
Addition of interleukin-8 to Huh7 cells inhibited the antiviral activity of interferon and, similarly to NS5A, reduced the induction
by interferon- of selective genes including OAS-p69. Our findings provide a mechanism for NS5A-mediated interferonINTRODUCTION
Hepatitis C virus (HCV) is a positive-stranded RNA virus
classified in the Flaviviridae family, which exhibits marked
viral heterogeneity (Brechot, 1996). The polyprotein precur-
sor is co- and posttranslationally processed to yield mature,
structural (C, E1, and E2) and nonstructural (p7, NS2, NS3,
NS4A, NS4B, NS5A, and NS5B) proteins (Bartenschlager et
al., 1993; Grakoui et al., 1993; Selby et al., 1993). HCV is a
highly prevalent pathogen (Alter, 1997) and 70–80% of
acutely infected subjects will become chronic carriers, with
a high subsequent risk of progression to liver cirrhosis and
hepatocarcinoma (Di Bisceglie, 1995). Interferon- (IFN-)
therapy ( ribavirin) is the only currently available treatment
for HCV, but is not effective for a majority of patients
(McHutchinson et al., 1998; McHutchinson and Poynard,
1999; Schalm et al., 1999). Several studies have correlated
IFN response with substitutions in a region of the nonstruc-
tural 5A (NS5A) gene product of HCV, referred to as the
interferon sensitivity-determining region (ISDR; position
2209–2248) (Enomoto et al., 1995, 1996; Gerotto et al., 2000;
Halfon et al., 2000; Watanabe et al., 2001; Witherell and
Beineke, 2001). Such a strict correlation between ISDR
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272mutations and treatment efficacy has not, however, been
verified in other studies (Hofgartner et al., 1997; Khorsi et al.,
1997; Pawlotsky et al., 1998; Rispeter et al., 1998; Squadrito
et al., 1997, 1999; Zeuzem et al., 1997; Sarrazin et al., 1999;
Nousbaum et al., 2000). Expression of genotype-1b NS5A
protein is sufficient to partially inhibit the antiviral activity of
IFN- in several cell types (Aizaki et al., 2000; Paterson et
al., 1999; Polyak et al., 1999; Song et al., 1999), including
hepatoma cells (Podevin et al., 2001). Surprisingly, this in-
hibitory effect of NS5A did not correlate with clinical re-
sponse (Aizaki et al., 2000; Paterson et al., 1999; Podevin et
al., 2001). It has been reported that NS5A binds the dimer-
ization domain of the IFN-inducible dsRNA-dependent pro-
tein kinase (PKR) and abolishes its catalytic activity (Gale et
al., 1997, 1998). However, we and others suggested that
PKR may not mediate the inhibition by NS5A of the IFN
antiviral activity (Francois et al., 2000; Podevin et al., 2001).
Therefore, despite numerous studies, the mechanisms of
viral resistance to IFN- therapy remain largely undefined.
Here we used microarray technologies to identify gene
expression profiles of IFN-treated hepatocytic cells ex-
pressing NS5A natural mutants isolated from patients re-
sistant or responsive to IFN therapy.
RESULTS
Gene expression profile in IFN-treated Huh7 cellsresistance. © 2002 Elsevier Science (USA)
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0042-6822/02 $35.00We wished to compare the interferon responsiveness
in Huh7 cells expressing a NS5A mutant isolated from am on
patient infected with HCV genotype 1b, who was a non-
responder to IFN therapy. We previously established sta-
ble clones expressing this NS5A sequence and reported
that the antiviral activity of IFN against vesicular stoma-
titis virus (VSV) and encephalomyocarditis virus (EMCV)
is inhibited in these cells compared to control clones
expressing the empty vector (Podevin et al., 2001). In the
present study, we used two control clones transfected
with the empty vectors (T1 and T2) and two clones stably
expressing NS5A (F1 and F11) (Podevin et al., 2001). The
expression level of NS5A in these cells is shown in Fig.
1. In two independent experiments, T1 and T2 Huh7
control clones were treated with IFN- for 24 h. RNA
transcript levels for different genes were determined in
untreated and IFN-treated cells, using oligonucleotide
arrays. Transcripts for 40% of the 6300 unique genes
assessed were detected in Huh7 cells. We identified a
subset of genes that significantly differed in their expres-
sion levels following IFN treatment by twofold or greater,
in both control clones and in all experiments (P value
0.05). The 53 genes identified are presented in Table 1.
The large majority of the modified genes (50 of 53) were
up-regulated upon IFN- treatment and represented
genes known to be inducible by IFN. This group included
the following: Mx1, 2,5-oligoadenylate synthetase 1 and
2 (OAS-p40/46, OAS-p69), the protein kinase PKR, signal
transducer and activator of transcription 1 (STAT1), inter-
feron-stimulated transcription factor 3 (ISGF3), interfer-
on-induced proteins 15, 20, 27, 35, 41, 56, and 75, promy-
elocytic leukemia 1 and 2 (PML1, PML2), MHC class I
molecules, Mac-2 binding protein (Mac-2bp), phospho-
lipid scramblase, N-myc (and STAT) interactor (NMI), and
beta-2 microglobulin. Some of the IFN-regulated genes
found were not previously known to be modified by
interferon and included the small inducible (Cys-Cys)
cytokine LARC (also designated Exodus 1 or MIP-3a) and
the TNF-inducible protein A20.
Effect of NS5A on IFN-regulated genes
A similar analysis was performed on the NS5A-ex-
pressing Huh7 clones F1 and F11. Genes showing sig-
nificant differences in response to IFN- between NS5A-
expressing cells and controls (P value 0.05) were se-
lected. Expression of most of the IFN-regulated genes
was modified similarly by IFN-, in NS5A-expressing
cells and in control cells. These included PKR, Mx1, and
OAS-p40/46, in agreement with our preliminary observa-
tion (Podevin et al., 2001). Of the 53 genes, 9 failed to be
induced by IFN to the same extent in NS5A-expressing
clones compared to controls (Table 2). Induction of Mac-
2bp, HLA-B, phospholipid scramblase, LARC, NMI,
ISG20, and complement component 3 by IFN was re-
duced by approximately two- to threefold, whereas no
induction of OAS-p69 and A20 was observed in NS5A-
expressing cells following IFN treatment.
To validate the microarray data, semiquantitative or
real-time PCR amplifications were undertaken for Mac-
2bp, phospholipid scramblase, OAS-p69, OAS-p40/46,
ISG20, and LARC transcripts (Fig. 2). The PCR and mi-
croarray data were highly concordant for these six
genes. Mac-2bp is not expressed in untreated Huh7
cells and its induction by interferon is reduced by 2-fold
in NS5A-expressing cells compared to control cells.
Phospholipid scramblase is expressed in untreated cells
and its induction is also reduced by 2-fold in NS5A-
expressing cells compared to control cells. We com-
pared IFN induction of OAS-p40/46 and OAS-p69. By
microarray, we observed an up-regulation of OAS-p40/46
expression by 22-fold in IFN-treated, control, and NS5A-
expressing cells. Similar data were obtained by RT-PCR.
In contrast, OAS-p69 expression is induced by IFN- in
control cells but not in NS5A-expressing cells as dem-
onstrated by microarray and RT-PCR experiments. A re-
duced induction of ISG20 and LARC transcripts in NS5A-
expressing cells was also demonstrated by RT-PCR and
real-time PCR, respectively. However, this reduction was
largely due to an increased expression of both ISG20
and LARC genes in NS5A-expressing cells compared to
control cells, in the absence of any IFN treatment.
Effect of NS5A on gene expression profile in Huh7
cells
Our previous data suggested that NS5A also modifies
the expression of some IFN-regulated genes in the ab-
sence of IFN treatment. Thus, we analyzed the effect of
NS5A expression in Huh7 cells, using oligonucleotide
arrays. To examine the role of NS5A of gene expression
in Huh7 cells, we compared transcript levels in the two
F1 and F11 NS5A-expressing clones and in the two T1
and T2 control clones, using oligonucleotide microar-
rays. Two independent experiments were performed and
selection was based on a P value of 0.05 or less. Ap-
proximately 100 genes were significantly up- or down-
regulated in the NS5A-expressing Huh7 clones. These
genes included IFN-inducible genes or genes known to
modulate IFN activity, such as ISG20 and LARC, which
FIG. 1. NS5A expression in Huh7 cell clones. Total proteins from
Huh7 clones stably expressing NS5A (F1 and F11) and from control
clones (T1 and T2) were separated by SDS–PAGE, transferred to nitro-
cellulose membrane, and probed with anti-NS5A and anti--actin an-
tibodies.
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showed a 2-fold increase. Additionally, we observed a
5-fold induction of interleukin-8 (IL-8) expression and a
2-fold down-regulation of STAT6 in NS5A-expressing
cells. Real-time PCR experiments were performed on the
samples analyzed by microarrays. These results con-
firmed the regulation of IL-8 and STAT6 by NS5A (Fig. 3).
TABLE 1
Regulated mRNAs in IFN-Treated Huh7 Cells
GenBank Accession No. Description Fold change
M33882 Interferon-inducible protein p78 (Mx1) 55
M13755 Interferon-stimulated protein, 15 kDa (ISG15) 43
J04164 Interferon-induced transmembrane protein 1 (9–27) 39.5
M24594 Interferon-induced protein 56 29
L13210 Mac-2 binding protein (Mac-2bp) 25
X67325 Interferon--inducible protein 27 24
X02874 2,5-Oligoadenylate synthetase 1 (OAS-p40/46) 22
U22970 Interferon -inducible protein (G1P3) 16
X57351 Interferon-induced transmembrane protein 2 (1-8D) 13
U72882 Interferon-induced protein 35 13
AF008445 Phospholipid scramblase 12.5
D28137 Bone marrow stromal cell antigen 2 (BST2) 12
X58536 Major histocompatibility complex, class I, C (HLA-C) 9.5
D49824 Major histocompatibility complex, class I, B (HLA-B) 9
M97936 Signal transducer and activator of transcription 1, 91 kDa (STAT1) 8
M87503 Interferon-stimulated transcription factor 3,  (48 kDa) (ISGF3) 7
U50648 Interferon-inducible RNA-dependent protein kinase (PKR) 5
M87434 2-5-Oligoadenylate synthetase 2 (OAS-p69) 5
U52513 RIG-G 4.5
M55542 Guanylate binding protein 1, interferon-inducible, 67 kDa (GBP1) 4.5
X04729 Plasminogen activator inhibitor, type 1 3.5
M74447 ATP-binding cassette, subfamily B, member 3 3.4
X02530 IP10 3
L22343 Interferon-induced protein 75, 52 kDa 3
X62741 Proteasome subunit,  type, 9 3
L22342 Interferon-induced protein 41, 30 kDa 2.8
U34605 Retinoic acid- and interferon-inducible protein, 58 kDa (RI58) 2.6
M83667 CCAAT/enhancer binding protein (C/EBP),  2.5
V00594 Metallothionein 2A 2.5
M20022 Major histocompatibility complex, class I, E (HLA-E) 2.5
D50919 KIAA0129 2.5
U32849 N-myc (and STAT) interactor (NMI) 2.4
D32129 Major histocompatibility complex, class I, A (HLA-A) 2.4
D45248 Proteasome activator subunit 2 (PA28 ) 2.3
U88964 Interferon stimulated gene, 20 kDa (ISG20) 2.3
M79463 Promyelocytic leukemia PML-2 2.3
M37435 Colony-stimulating factor 1 (CSF1) 2.2
U64197 LARC/MIP-3a/Exodus 1 2.2
M24283 Intercellular adhesion molecule 1 (ICAM1) 2.2
M79462 Promyelocytic leukemia PML-1 2.2
X90846 Mitogen-activated protein kinase kinase kinase 10 (MAP3K10) 2.2
L07633 Proteasome activator subunit 1 (PA28 ) 2.1
U37518 TNF-related apoptosis-inducing ligand (TRAIL) 2.1
M59465 TNF -induced protein 3 (A20) 2.1
K02765 Complement component 3 2
J04080 Complement component 1 2
S82297 -2 microglobulin 2
U10439 Adenosine deaminase (ADAR) 2
Z29083 5T4 oncofetal trophoblast glycoprotein 2
Z36714 Cyclin F 3.5
X15882 Collagen, type VI,  2 3
M11437 Kininogen 2.1
Note. RNA from untreated and IFN-treated T1 and T2 Huh7 clones were hybridized onto Affymetrix oligonucleotide arrays and quantified as
indicated under Materials and Methods. For each gene, the fold change was calculated by Affymetrix software. The  indicates fold change
calculation for which the smaller value is replaced by an estimate of the minimum value for detectable transcripts.
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Following normalization with -actin mRNA levels, we
observed up-regulation of IL-8 mRNA expression by 9-
and 3.4-fold in F1 and F11 clones, respectively. STAT6
expression was decreased by 1.7- and 3.2-fold in F1 and
F11 clones, respectively.
Transient transfection assays were performed as a
TABLE 2
mRNAs Differently Regulated by IFN in NS5A-Expressing Huh7 Cells
GenBank
Accession No. Description
Fold change
P valueT1/T2 F1/F11
L13210 Mac-2 binding protein (Mac-2bp) 25 13.5 0.027
D49824 Major histocompatibility complex, class I, B (HLA-B) 15.5 6 0.002
AF008445 Phospholipid scramblase 12.5 6.5 0.005
M87434 2-5-Oligoadenylate synthetase 2 (OAS-p69) 5 1.2 0.002
U32849 N-myc (and STAT) interactor (NMI) 2.4 1.8 0.035
U88964 Interferon-stimulated gene (20 kDa) (ISG20) 2.3 1.2 0.037
U64197 LARC/Exodus 1/Mip-3a 2.2 1.3 0.012
M59465 Tumor necrosis factor, -inductible protein 3 (A20) 2.1 1.1 0.014
K02765 Complement component 3 2 1.4 0.025
Note. RNA from untreated and IFN-treated F1 and F11 Huh7 clones was hybridized onto Affymetrix oligonucleotide arrays and quantified as
indicated under Materials and Methods. For each gene, the fold change was calculated by Affymetrix software. Genes differently modulated by IFN
in these clones compared to T1 and T2 clones (P  0.05) were selected. The  indicates the fold change calculation for which the smaller value
is replaced by an estimate of the minimum value for detectable transcripts.
FIG. 2. Effect of NS5A on the expression of some IFN-inducible genes. (A) Total RNA from T1, T2, F1, and F11 Huh7 clones, treated for 24 h with
medium alone () or with IFN- (), was reverse-transcribed and PCR amplification was performed for Mac-2bp, phospholipid scramblase, OAS-p69,
OAS-p40/46, ISG20, and actin genes as described under Materials and Methods. Lane (0) represents the negative control, which was the product
of PCR where RNA was omitted. (B) LARC mRNA levels were measured in the same cells by real-time quantitative RT-PCR, using the Roche system.
The data are presented as ratios of LARC mRNA to -actin mRNA.
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direct approach to determine the effect of NS5A on the
expression of IL-8, STAT6, LARC, and ISG20. Three NS5A
expression plasmids, including NR1 expressed in F1 and
F11 cells and NR2 and R1 corresponding to full-length
NS5A sequences isolated from a nonresponder and a
responder patient, respectively (Podevin et al., 2001),
were transfected into Huh7 cells. Transfection with a
construct encoding the green fluorescence protein dem-
onstrated a transfection efficiency of approximately 50–
60%. NS5A protein expression was analyzed 48 h post-
transfection, by Western blotting (Fig. 4). RNA levels were
analyzed by microarray analysis, in two independent
experiments. Expression of STAT6, LARC, and ISG20 did
not change in Huh7 cells upon transient expression of
any NS5A sequence, NR1, NR2, or R1. However, IL-8
expression was significantly induced (P  0.009) in
Huh7 cells transiently expressing NS5A NR1 compared
to control cells expressing the vector alone (data not
shown). A similar induction was also observed in cells
expressing the NS5A mutants NR2 and R1.
Expression of IL-8 protein in Huh7 cells expressing
NS5A
We performed further analysis of the expression of IL-8
in the NS5A-expressing clones F1 and F11. The level of
IL-8 protein was quantified by ELISA after 24, 48, and
72 h of culture (Fig. 5). The IL-8 level did not differ
between the two control clones T1 and T2, slightly rising
with increased time in culture. The IL-8 pattern of expres-
sion in these cells was characterized by a slight increase
during the culture. In contrast, we observed a strong
increase in the IL-8 level at 48 and 72 h in the superna-
tant of the two clones, F1 and F11, expressing NS5A.
After 72 h, IL-8 accumulated in the supernatant of control
cells, reaching 4200 and 2800 pg/ml in T1 and T2, re-
spectively. Concentrations of IL-8 were 9600 and 16,000
pg/ml in F1 and F11 clones, respectively.
Effect of IL-8 on IFN-mediated antiviral activity in
Huh7 cells
It has been reported that IL-8 reduces the antiviral
activity of IFN- in fibroblastic cells (Khabar et al., 1997).
To examine the potential effect of IL-8 on the IFN-medi-
ated antiviral activity in hepatoma cells, viral rescue
assays were performed using VSV as the challenge
FIG. 3. Effect of NS5A on the expression of IL-8 and STAT6 mRNA. IL-8 and STAT6 mRNA levels were measured in T1, T2, F1, and F11 clones by
real-time quantitative RT-PCR, using the Roche system. The data are presented as ratios of IL-8 mRNA (A) or STAT6 mRNA (B) to -actin mRNA.
FIG. 4. NS5A expression in Huh7 cells following transient transfec-
tions. Huh7 cells were transfected with NR1, NR2, and R1 NS5A-
expressing plasmids or with the empty vector (C). After 48 h, total
proteins were separated by SDS–PAGE, transferred to nitrocellulose
membrane, and probed with anti-NS5A and anti--actin antibodies.
FIG. 5. Expression of IL-8 protein in NS5A-expressing cells as de-
termined by ELISA. T1, T2, F1, and F11 Huh7 clones were cultured for
3 days and IL-8 was measured in the supernatants every 24 h, by
ELISA.
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virus. Huh7 cells were pretreated or not with IL-8 for 20 h
prior to addition of IFN-. Cells were then infected with
VSV for 24 h and virus titers were measured by TCID50
assay. We found that IFN- inhibited replication of VSV
by 0.9 log. In contrast, the antiviral activity of IFN was
reduced by 3.2-fold in the presence of IL-8 (Fig. 6). Thus,
IL-8 partially inhibits the antiviral activity of IFN- in
hepatocytic cells.
Effect of IL-8 on specific IFN-regulated genes
We wished to investigate the role of IL-8 up-regulation
by NS5A, in the reduced induction by IFN- observed on
selective genes in NS5A-expressing Huh7 cells. Semi-
quantitative PCR amplifications were undertaken for
Mac-2bp, phospholipid scramblase, OAS-p69, ISG20,
and LARC transcripts. Induction of Mac-2bp, phospho-
lipid scramblase, OAS-p69, and ISG20 following IFN-
treatment was reduced in IL-8-pretreated Huh7 cells
compared to control cells (Fig. 7). In addition, IL-8 in-
duced ISG20 expression, similarly to NS5A. No effect of
IL-8 on the induction of LARC expression by IFN- was
observed (data not shown). We conclude that up-regula-
tion of IL-8 by NS5A partially mediates the reduction of
IFN induction observed in NS5A-expressing cells, for
selected IFN-inducible genes.
DISCUSSION
Several studies demonstrated a major role of the non-
structural HCV NS5A protein in IFN resistance (Enomoto
et al., 1996; Gale et al., 1997; Paterson et al., 1999;
Podevin et al., 2001; Polyak et al., 1999; Song et al., 1999).
In order to develop a better understanding of the mech-
anism involved, we utilized oligonucleotide microarrays
for a systematic quantitative analysis of IFN-inducible
genes in hepatoma cells expressing NS5A. We previ-
ously reported that IFN antiviral activity is partially inhib-
ited in these NS5A-expressing Huh7 cells (Podevin et al.,
2001). Here, we identified 53 genes regulated by IFN-
treatment. A large number of these genes have been
previously identified as being regulated by IFN- in a
fibrosarcoma cell line, using oligonucleotide arrays (Der
et al., 1998). Moreover, many genes consisted of known
interferon-stimulated genes, as indicated in previously
published studies. The remaining genes representing
novel IFN-regulated genes include the small inducible
cytokine LARC (Exodus-1 or MIP-3a) and the TNF-induc-
ible protein A20.
Nine of the 53 genes identified in control cells did not
respond to the same extent to IFN- in cells expressing
NS5A (P  0.05). The induction by IFN- was reduced
in NS5A-expressing cells compared to control cells by
approximately twofold, for Mac-2bp, HLA-B, phospho-
lipid scramblase, NMI, A20, and complement component
FIG. 7. Effect of IL-8 on the expression of specific IFN-inducible
genes. Huh7 cells, control (C) or pretreated with IL-8 (IL-8), were
subsequently stimulated for 24 h with medium alone () or with IFN-
(). Total RNA was isolated and reverse-transcribed, and PCR ampli-
fication was performed for Mac-2bp, phospholipid scramblase, OAS-
p69, ISG20, and actin genes as described under Materials and Meth-
ods. Lane (0) represents the negative control, which was the product of
PCR where RNA was omitted.
FIG. 6. Effect of IL-8 on VSV challenge in IFN-treated Huh7 cells.
Huh7 cells were pretreated with IL-8 followed by IFN- for 24 h before
infection with VSV at a multiplicity of infection of 1 PFU/cell. At 1 day
postinfection, virus titers were measured. Bars represent the mean 
SEM of four independent experiments.
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3. No antiviral activity for these genes has been de-
scribed so far. Elevated levels of Mac-2bp have been
found in the sera of patients with various types of cancer
and viral infection, as well as in patients with hepatocel-
lular carcinoma and cirrhosis (Correale et al., 1999).
Serum Mac-2bp levels are also increased in chronic viral
hepatitis patients, being significantly higher in HCV than
in HBV patients (Artini et al., 1996). Interestingly, it has
been suggested that Mac-2bp levels could be an inde-
pendent predictor of disease severity and of nonrespon-
siveness to IFN- treatment in chronic HCV patients
(Artini et al., 1996; Kittl et al., 2000). Hepatocellular ex-
pression of HLA-A, B, and C molecules was also re-
ported to predict primary response to interferon in pa-
tients with chronic hepatitis C (Ballardini et al., 1994,
1995). Phospholipid scramblase regulates lipoprotein
levels and it has been suggested that this protein medi-
ates the redistribution of plasma membrane phospholip-
ids in apoptotic cells (Zhao et al., 1998). NMI, a protein
with 25% amino acid identity with the interferon-inducible
protein IFP35, interacts with c-Myc, N-Myc, Max, and
Fos. NMI and IFP-35 also associate into a high-molecu-
lar-mass complex (Chen et al., 2000). The zinc finger
protein A20 is an inhibitor of NF-B activity and TNF-
mediated apoptosis (reviewed by Beyaert et al., 2000). Its
expression is inducible by a variety of stimuli including
cytokines such as TNF and viral products. However,
induction of A20 by IFN has not been reported so far.
Using A20-deficient mice, a recent study demonstrated
that A20 is critical for limiting inflammation by terminat-
ing TNF-induced NF-B responses in vivo (Lee et al.,
2000). The liver is the major expression site of comple-
ment component 3, the central mediator of complement
activation. The number of viruses found to interact with
molecules of the complement system is growing and the
widespread presence of complement-modifying proteins
in pathogenic viruses suggests that they may play an
important role in disease progression. The inhibition of
C3 expression by NS5A in IFN-treated cells suggests a
possible immunoregulatory role of HCV NS5A protein.
The 2,5-oligoadenylate synthetases (OAS) represent
a family of IFN-induced proteins implicated in the antivi-
ral action of IFN. Three forms of human OAS have been
described and are encoded by three distinct genes
(Hovanessian et al., 1987; Hovnanian et al., 1998). The
different forms of OAS have distinct enzymatic parame-
ters, suggesting that they might have different specific
functions (Marie et al., 1997; Rebouillat and Hovanes-
sian, 1999). In contrast to OAS-p40/46 mRNA, OAS-p69
mRNA failed to be induced by IFN in cells expressing
NS5A. Interestingly, it has been reported that OAS-p69
can mediate the antiviral action of IFN (Marie et al.,
1999). The promoter region of the genes encoding OAS-
p40/46 and OAS-p69 have a typical functional IFN-stim-
ulated response element but the OAS-p69 promoter is
more complex and at least three regulatory elements
cooperate to give a maximal activation after treatment by
IFN (Floyd-Smith et al., 1999; Wang and Floyd-Smith,
1998). The precise role of OAS-p69 in IFN resistance
induced by NS5A remains to be determined.
In the absence of any IFN treatment, NS5A also mod-
ified the expression of genes modulated by IFN or known
to modulate IFN activity. These included ISG20, LARC,
STAT6, and IL-8. ISG20 is closely associated with the
PML and SP100 genes (Gongora et al., 1997). LARC (also
called Exodus 1 or MIP-3a) is a chemokine that was
recently characterized, expressed mainly in liver. LARC
is up-regulated by mediators of inflammation such as
TNF and is significantly chemotatic for lymphocytes
(Hieshima et al., 1997). STAT6 mediates responses to
IL-12 and IL-4 (Takeda and Akira, 2000) and it has been
shown that IFN inhibits the IL-4 and IL-13 induction of a
few genes, by inhibiting STAT6 activity (Dickensheets
and Donnelly, 1999). In addition, STAT6 mediates sup-
pression of STAT1 and NF-B-dependent transcription
(Ohmori and Hamilton, 2000). Most interestingly, we ob-
served a strong up-regulation of IL-8 mRNA and protein
expression in Huh7 cells expressing NS5A. This is in
agreement with recent data demonstrating an induction
of IL-8 expression by NS5A in HeLa cells (Polyak et al.,
2001a). It was also reported that IL-8 reduces the antivi-
ral activity of IFN- in fibroblasts and HeLa cells (Khabar
et al., 1997). We demonstrated a similar inhibition of IFN
antiviral activity by IL-8 in hepatocytic Huh7 cells. IL-8
expression is induced by several viruses including hu-
man herpesvirus 6 (Inagi et al., 1996), cytomegalovirus
(Murayama et al., 1998), and respiratory syncitial virus
(Becker et al., 1991; Black et al., 1998; Fiedler et al., 1995,
1996) through NF-B and AP-1 signaling (Casola et al.,
2000; Mastronarde et al., 1996, 1998). It has been re-
ported that IL-8 is significantly elevated in patients with
chronic HCV infection and that the level of IL-8 correlates
with liver fibrosis (Kaplanski et al., 1997). IL-8 levels are
also more elevated in sera of patients with hepatocellu-
lar carcinoma (HCC) and chronic active hepatitis asso-
ciated with HCV (Al-Wabel et al., 1995; Miyamoto et al.,
1998). Additionally, cytotoxic lymphocytes from patients
infected with HCV produce IL-8 (Koziel et al., 1995).
Remarkably, elevated levels of IL-8 in HCV-infected pa-
tients, with significantly higher IL-8 levels in patients who
did not respond to IFN therapy, were recently reported
(Polyak et al., 2001b). HCV core protein activates the IL-8
promoter through NF-B and AP-1 (Kato et al., 2000).
Here we show that the induction of IL-8 may also be
dependent on NS5A in hepatocytic cells. Induction of
IL-8 mRNA by NS5A was observed 48 h posttransfection
and remarkably, all three NS5A sequences tested, ob-
tained from patients either responsive or not to IFN
therapy, did induce IL-8 expression.
The release of IL-8 induced by HCV viral proteins such
as NS5A may contribute to the pathogenesis of HCV-
induced liver damage as well as to the mechanisms of
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IFN resistance. Remarkably, all three NS5A sequences
analyzed, which were derived from patients who were
responders and nonresponders to IFN therapy, induced
IL-8 expression, suggesting that other mechanisms are
important for the final phenotypic effect of NS5A. This
emphasizes the relevance of a global approach to study
NS5A-related biological effects. We also demonstrated
that NS5A inhibited the induction by IFN of selected
genes including OAS-p69. These effects may also con-
tribute to the resistance to IFN mediated by NS5A. In
addition, NS5A modifies various activities in response to
IFN that would be predicted to provide survival value for
the virus by subverting host defense and apoptotic
mechanisms.
MATERIALS AND METHODS
Cell culture
The human hepatoma Huh7 cell line was maintained
in Dulbecco’s modified Eagle’s medium (DMEM, Gibco
BRL) supplemented with 10% fetal calf serum (FCS), 2
mM L-glutamine, 100 U/ml penicillin, and 100 g/ml
streptomycin. We recently established stable Huh7
clones expressing three NS5A mutants (Podevin et al.,
2001). These three NS5A sequences were obtained from
patients infected with genotype 1b HCV who were re-
sponders or nonresponders to IFN therapy. Herein, we
used the control clones T1 and T2 and two stable clones,
F1 and F11, expressing the NS5A mutant NR1, isolated
from a nonresponder patient (Podevin et al., 2001). The
established clones were grown in DMEM containing 10%
FCS and 400 g/ml of geneticin (Gibco BRL). When
indicated, the cells were treated with recombinant IFN-
(Schering-Plough) for 24 h at a concentration of 100 U/ml
or with hIL-8 (R&D Systems) for 24 h at a concentration
of 0.15 g/ml.
Transient NS5A expression
Huh7 cells were plated in 100-mm dishes at 4  105
cells/dish. Twenty-four hours later, the cells were trans-
fected by addition of 30 l of the Lipofectamine trans-
fection reagent (Gibco BRL) and 15 g of the plasmid
containing the NR1, the NR2, or the R1 NS5A sequence
or of the empty vector, in OPTIMEM I medium (Gibco
BRL). NR1 and NR2 represent NS5A natural mutants
isolated from patients infected with HCV-1b and who
were nonresponders to IFN therapy, whereas R1 corre-
sponds to an NS5A natural mutant isolated from a patient
who responded to IFN therapy (Podevin et al., 2001). The
cells were cultured for an additional 48 h in DMEM
supplemented with 7.5% FCS. In additional experiments,
Huh7 cells were cotransfected with 4 g of the pEGFP
vector encoding the green fluorescence protein (Clon-
tech, France) as a monitor for transfection efficiency.
Preparation of cRNA and gene chip hybridization
Total RNA was isolated using Trizol reagent (Gibco
BRL), followed by clean-up on an RNeasy spin column
(Qiagen), and then used to generate cRNA probes. Prep-
aration of cRNA, hybridization, and scanning of the Hu-
GeneFL arrays were performed according to the manu-
facturer’s protocol (Affymetrix, Santa Clara, CA). Briefly, 5
g of total RNA was converted into double-stranded
cDNA by reverse transcription using a cDNA synthesis
kit (Superscript Choice System, Gibco BRL) with an oli-
go(dT)24 primer containing a T7 RNA polymerase pro-
moter site added 3 of the poly(T) (Genset, La Jolla, CA).
Following second-strand synthesis, labeled cRNA was
generated from the cDNA sample by an in vitro transcrip-
tion reaction supplemented with biotin-11–CTP and bi-
otin-16–UTP (Enzo, Farmingdale, NY). The labeled cRNA
was purified by using RNeasy spin columns (Qiagen).
Fifteen micrograms of each cRNA was fragmented at
94°C for 35 min in fragmentation buffer (40 mM Tris–
acetate (pH 8.1), 100 mM potassium acetate, 30 mM
magnesium acetate) and then used to prepare 300 l of
hybridization cocktail (100 mM MES, 1 M NaCl, 20 mM
EDTA, 0.01% Tween 20) containing 0.1 mg/ml of herring
sperm DNA (Promega, Madison, WI), 500 g/ml acety-
lated BSA (Gibco BRL), and a mixture of control cRNAs
for comparison of hybridization efficiency between ar-
rays and for relative quantitation of measured transcript
levels. Prior to hybridization the cocktails were heated to
94°C for 5 min, equilibrated at 45°C for 5 min, and then
clarified by centrifugation (16,000 g) at room temperature
for 5 min. Aliquots of each sample (10 g of fragmented
cRNA in 200 l of hybridization cocktail) were hybridized
to HuGeneFL arrays at 45°C for 16 h in an oven set at 60
rpm. The arrays were then washed with nonstringent
wash buffer (6X SSPE) at 25°C, followed by a wash with
stringent wash buffer (100 mM MES (pH 6.7), 0.1 M NaCl,
0.01% Tween 20) at 50°C, stained with streptavidin–
phycoerythrin (Molecular Probes), washed again with 6X
SSPE, and stained with biotinylated anti-streptavidin IgG,
followed by a second staining with streptavidin–phyco-
erythrin and a third washing with 6X SSPE. The arrays
were scanned using the GeneArray scanner (Affymetrix).
Data analysis was performed using GeneChip 4.0 soft-
ware. The software includes algorithms that determine
whether a gene is absent or present and whether the
expression level of a gene in an experimental sample is
significantly increased or decreased relative to a control
sample.
SDS–PAGE and Western blotting
Cells were lysed in 20 mM Tris–HCl, pH 7.5, buffer
containing 5 mM EDTA and 100 mM KCl. Total proteins
(50 g) were diluted in Laemmli sample buffer, resolved
by SDS–PAGE in a 9% polyacrylamide gel, and trans-
ferred onto a 0.22-m nitrocellulose membrane (Schlei-
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cher and Schuell, Dasel, Germany). The membranes
were incubated for 2 h in blocking buffer containing 5%
milk in 10 mM Tris–HCl, pH 7.5; 2.5 mM EDTA, pH 8; 50
mM NaCl. Subsequent incubation was performed for 2 h
with monoclonal antibodies against NS5A (Biogenesis)
(1/1000) or actin (ICN) (1/20,000). After three washes, the
membranes were finally incubated for 1 h with a horse-
radish peroxidase-conjugated anti-mouse antibody (Am-
ersham) (1/2000). Immunodetection was realized by en-
hanced chemiluminescence reagents (Amersham) fol-
lowed by autoradiography on hyperfilm MP (Amersham).
RT-PCR
Single-stranded cDNA was synthesized from total RNA
using Superscript II reverse transcriptase (Gibco) and
random hexamers (Gibco) as primers. Preliminary exper-
iments were performed to determine the conditions in
which cDNAs were amplified in the linear region of the
PCR curve. The reaction mixture was composed of 1 l
of cDNA template (diluted 1/5) obtained from 1 g of
extracted RNA; 25 pmol of primers; 25 nmol of each
dNTP; 2.5 U of Taq DNA polymerase (Gibco); 10 l of 10
PCR buffer in a final volume of 50 l. The nucleotide
sequence of primers and corresponding annealing tem-
peratures used are as indicated (Table 3). PCR amplifi-
cation conditions were as follows: denaturation at 94°C
for 5 min, amplification for 25, 30, or 35 cycles composed
of denaturation at 94°C for 30 s, annealing for 30 s, and
extension at 72°C for 1 min, followed by a final extension
at 72°C for 10 min. The expression level for each tran-
script was evaluated following ethidium bromide staining
by densitometric scanning and analysis using Image
Quant Software.
For real time RT-PCR, total RNA was amplified by
RT-PCR using a LightCycler instrument (Roche Molecular
Biochemicals), which amplifies and monitors by fluores-
cence assay the development of target nucleic acid after
each cycle. The RT-PCRs were performed in capillaries
(Roche) with 200 ng of total RNA in a total volume of 20
l using the LightCycler-RNA amplification Kit SYBR
green I (Roche) and according to the manufacturer’s
instructions. The amplification steps were as follows:
reverse transcription for 10 min at 55°C, denaturation for
1 min at 95°C, 45 cycles consisting of denaturation for
1 s at 95°C, annealing for 8 s at 60°C, and extension for
15 s at 72°C. Analysis of the PCR amplification and probe
melting curves was accomplished through the use of
LightCycler software. Actin mRNA was used to normalize
the amounts of input mRNAs in each sample.
Quantitative enzyme-linked immunosorbent assay
(ELISA) for interleukin-8
Amounts of IL-8 present in the culture medium of the
T1, T2, F1, and F11 Huh7 clones were measured by ELISA
with the Quantikine human IL-8 kit (R&D Systems), after
24, 48, and 72 h of culture. Aliquots of 50 l of diluted
(1/10 and 1/100) and undiluted media were used for
ELISA according to the manufacturer’s instructions. The
captured IL-8 was then quantitated at 450 nm in a spec-
trophotometer. Two independent experiments as well as
two independent measures were performed for each
sample.
Virus rescue assay
Stocks of VSV were prepared from the supernatants of
virus-infected L929 mouse fibroblast cells and exhibited
TABLE 3
Primer Sequences
Gene Sequence Product size (bp) Annealing temperature (°C)
Actin 5-ATCATGTTTGAGACCTTCAA-3
644 60
5-TTG CGCTCAGGAGGAGCAAT-3
IL-8 5-ATGACTTCCAAGCTGGCCG-3
291 62
5-CTCAGCCCTCTTCAAAAACTT-3
Mac-2bp 5-GCGAGGAGGCTCCACACGG-3
277 60
5-GGTGGCGTTCTCGAAGCCC-3
Phospholipid scramblase 5-CTTGTCTCGCTCGGGAGCGG-3
226 60
5-CTGGGCCAGGACCTGAATGG-3
OAS-p69 5-TTAAATGATAATCCCAGCCC-3
424 60
5-AAGATTACTGGCCTCGCTGA-3
OAS-p40/46 5-AGTTCTGTTGCCACTCTCTCTC-3
151 62
5-TCAGGAACCCACAGATGATG-3
ISG20 5-GGTGGTGGCCATGGACTGC-3
236 60
5-GCTTGCCTTTCAGGAGCTGC-3
LARC 5-CAAGAGTTTGCTCCTGGCTGC-3
148 60
5-CAGCTGCCGTGTGAAGCCC-3
STAT6 5-CAGAGCTACAGACCTATGGGG-3
180 60
5-GAAGATGCCGCAGGTGTTGG-3
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titers of 1.05  107 plaque-forming units (PFU) per milli-
liter. Huh7 cells were seeded in 6-well tissue culture
plates at a density of 2  105 cells/well. Recombinant
human IL-8 (R&D Systems) was added to the cells for
20 h at a concentration of 0.15 g/ml, followed by recom-
binant IFN- (Schering-Plough) for 24 h at a concentra-
tion of 200 U/ml. Cells were then infected with 0.1 ml of
VSV with a multiplicity of infection of 1 PFU/cell. After
adsorption for 30 min at room temperature, excess virus
was removed by washing with serum-free medium, and
fresh medium containing 2% FCS was added. At 24 h
postinfection, the supernatants were collected and clar-
ified. Following serial dilutions at 1/10, virus titers were
measured by TCID50 assays on L929 cells. Four indepen-
dent experiments were performed.
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